Previous 10 | Next 10 |
Global registrational Phase 3 study, ZILO-301, of zilovertamab in patients with MCL on track to be initiated in Q3 2022 Presenting interim clinical data update from the ongoing Phase 1/2 clinical trial of zilovertamab in combination with ibrutinib for patients with MCL and CLL...
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2022 financial results after the U.S. financial mar...
Celularity posted revenue of $21.3M and diluted EPS of -$1.49 for FY-2021. The Company received five FDA fast track/orphan-drug destinations in FY-2021 for its lead candidates. The stock price is up 38%+ since our last coverage in September 2021, however, the company is in need of...
Clinical-stage biopharmaceutical company Oncternal Therapeutics (NASDAQ:ONCT) on Wednesday said it has deprioritized further development of its small molecule inhibitor ONCT-216 for the treatment of Ewing sarcoma, a rare and aggressive form of bone cancer. The Company said it has discontinued...
Discontinued enrollment of Phase 1/2 trial of ONCT-216 in Ewing sarcoma Resources will be primarily reallocated to our zilovertamab global registrational Phase 3 study ZILO-301, which is expected to be initiated in Q3 2022 Focus on advancing preclinical assets for hemato...
Image source: The Motley Fool. Oncternal Therapeutics, Inc. (NASDAQ: ONCT) Q4 2021 Earnings Call Mar 10, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Oncternal Therapeutics, Inc. (ONCT) Q4 2021 Earnings Call Tran...
Oncternal Therapeutics, Inc. (ONCT) Q4 2021 Earnings Conference Call March 10, 2022 05:00 PM ET Company Participants Richard Vincent - Chief Financial Officer James Breitmeyer - President & Chief Executive Officer Salim Yazji - Chief Medical Officer Conference Call Participants Hartaj Sin...
Reached consensus with the FDA on the design and major details of the global Phase 3 Study ZILO-301 to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib, which is on track to be initiated in the second quarter of 2022 Interim Phase 1/2 results for z...
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2021 financial results after the U.S...
Oncternal Therapeutics (NASDAQ:ONCT) granted Susette Gorak, Senior Manager, Regulatory Affairs, an option to buy 12.5K common shares. The award was made on March 1, under Oncternal’s 2021 Employment Inducement Incentive Award Plan. The option has a 10-year term and an exercise pri...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer ...